Here are the 424B prospectus supplements from Verastem, Inc. (VSTM) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow VSTM and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VSTM filings page.
Verastem, Inc. (VSTM) is offering 30,937,500 shares of common stock at $8.00 per share and pre-funded warrants to purchase up to 312,503 shares at $7.9999 per warrant. The company estimates net proceeds of approximately $234.7 million after underwriting discounts and estimated offering expenses, for continued VS-7375 clinical development, working capital and other general corporate purposes. The warrants are immediately exercisable at $0.0001 per share, are subject to ownership limits, and Verastem does not intend to list them on an exchange.
In ongoing VS-7375 studies, the company reported a 41% confirmed objective response rate in second-line-or-later pancreatic cancer at 900 mg once daily (9 of 22 patients) and a 43% confirmed objective response rate in advanced non-small cell lung cancer at 600 mg once daily (10 of 23). The FDA accepted the company's Blister Pack NDA for priority review, and a first-line pancreatic cancer Phase 3 trial is planned to open by year-end 2026. Preliminary, unaudited third-quarter 2026 net product revenue is estimated at $23.9 million to $24.1 million, versus $11.2 million a year earlier. Michael Bailey is set to become president and CEO on January 1, 2027, succeeding Daniel W. Paterson, who intends to remain a director.
Verastem, Inc. is conducting a preliminary primary offering of common stock and pre-funded warrants, with net proceeds to the company intended for continued VS-7375 clinical development, working capital and other general corporate purposes. The warrants are immediately exercisable, subject to ownership limitations, and are not intended to be listed on an exchange.
Verastem, Inc. is conducting a public offering of 8,543,794 shares of common stock and pre-funded warrants to purchase up to 3,870,000 additional shares, at $7.25 per share and $7.2499 per pre-funded warrant. The deal is expected to raise approximately $84.1 million in net proceeds, or about $96.9 million if underwriters fully exercise their 1,862,069-share option. Verastem plans to use the cash to commercialize its FDA-accelerated approved AVMAPKI FAKZYNJA CO-PACK for KRAS mutant recurrent low grade serous ovarian cancer, advance clinical development of avutometinib, defactinib and VS-7375, and for working capital and general corporate purposes. The company estimates 75,292,640 shares outstanding after the offering (assuming no warrant exercises), and notes investors will face immediate dilution of $6.56 per share based on the $7.25 offering price.
Verastem, Inc. (VSTM) launched a preliminary prospectus supplement under Rule 424(b)(5) for a primary offering of common stock. The company also granted underwriters a 30‑day option to purchase additional shares, subject to customary underwriting discounts and commissions.
The company states its common stock last closed at $8.51 on The Nasdaq Capital Market on November 12, 2025. Net proceeds are intended to fund commercial activities for the AVMAPKI FAKZYNJA CO‑PACK in low‑grade serous ovarian cancer, continue clinical R&D for avutometinib, defactinib and VS‑7375, and for working capital and general corporate purposes.
As context, shares outstanding were 66,748,846 as of September 30, 2025. The prospectus notes a 60‑day lock‑up for the company and its directors and officers, with Jefferies, Guggenheim and Cantor as bookrunners. AVMAPKI FAKZYNJA CO‑PACK received FDA accelerated approval on May 8, 2025 for KRAS‑mutant recurrent LGSOC, with continued approval contingent on confirmatory data.